The Pharmacogenomics Journal Contents: Volume 22 Number 2

In this Issue: Review Article Article Consensus Statement Correction

The Pharmacogenomics Journal Contents: Volume 22 Issue 2

Review Article

Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review Joseph O'Shea, Mark Ledwidge, Joseph Gallagher, Catherine Keenan & Cristín Ryan Review Article | 22 February 2022 The Pharmacogenomics Journal 22 | doi:10.1038/s41397-021-00260-6

Article

Pharmacogenomic analysis of a genetically distinct Indigenous population Arvind Jaya Shankar, Sudhir Jadhao, Wendy Hoy, Simon J. Foote, Hardip R. Patel et al. Article | 25 November 2021 The Pharmacogenomics Journal 22 | doi:10.1038/s41397-021-00262-4

A single nucleotide polymorphism-based formula to predict the risk of propofol TCI concentration being over 4 µg mL−1 at the time of loss of consciousness Zhuoling Zheng, Faling Xue, Haini Wang, Yongqi He, Lingyi Zhang et al. Article | 22 January 2022 The Pharmacogenomics Journal 22 | doi:10.1038/s41397-021-00263-3

Identification of sex-specific genetic associations in response to opioid analgesics in a White, non-Hispanic cohort from Southeast Minnesota Guilherme S. Lopes, Jaime L. Lopes, Suzette J. Bielinski, Sebastian M. Armasu, Ye Zhu et al. Article | 31 January 2022 The Pharmacogenomics Journal 22 | doi:10.1038/s41397-022-00265-9

HLA-B*07:02 and HLA-C*07:02 are associated with trimethoprim-sulfamethoxazole respiratory failure Jennifer L. Goldman, Jenna O. Miller, Neil Miller, Robert Eveleigh, Andrew Gibson et al. Article | 16 February 2022 The Pharmacogenomics Journal 22 | doi:10.1038/s41397-022-00266-8

Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study Adrian I. Campos, Enda M. Byrne, Brittany L. Mitchell, Naomi R. Wray, Penelope A. Lind et al. Article | 29 January 2022 The Pharmacogenomics Journal 22 | doi:10.1038/s41397-022-00267-7

Consensus Statement

Evaluation of the EMPAR study population on the basis of metabolic phenotypes of selected pharmacogenes Jochen Fracowiak, Tatjana Huebner, Steffen Heß, Christoph Roethlein, Daria Langner et al. Consensus Statement | 31 January 2022 The Pharmacogenomics Journal 22 | doi:10.1038/s41397-022-00268-6

Correction

Correction to: PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors Julia C. F. Quintanilha, Alessandro Racioppi, Jin Wang, Amy S. Etheridge, Stefanie Denning et al. Correction | 21 December 2021 The Pharmacogenomics Journal 22 | doi:10.1038/s41397-021-00264-2

Correction to: Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review Joseph O'Shea, Mark Ledwidge, Joseph Gallagher, Catherine Keenan & Cristín Ryan Correction | 30 March 2022 The Pharmacogenomics Journal 22 | doi:10.1038/s41397-022-00273-9

Journal Info Submit Manuscript RSS Feed

This email has been sent to ignoble.experiment@arconati.us by The Pharmacogenomics Journal.

Unsubscribe Manage Alerts Privacy policy Contact us

Springer Nature Limited is a company registered in England and Wales under Company Number 785998 with its registered office at The Campus, 4 Crinan Street, London, N1 9XW, United Kingdom

Nature is part of Springer Nature. © 2022 Springer Nature Limited. All rights reserved.